Light Emitting Diode (LED) Therapy
Light emitting diode (LED) therapy is being proposed for the treatment of diabetic peripheral neuropathy, lymphedema, non-healing wounds and muscle pain. Treatment is based on the premise that LED therapy may cause an increase in nitric oxide concentrations that may lead to increased blood flow and promote vasodilatation.
LED therapy devices use one (monochromatic) or two wavelengths of infrared (invisible) light with or without red (visible) light. The light is measured in nanometers (880nm), with a higher nanometer number denoting a greater depth of tissue penetration. Treatment is administered several times a week over a period of weeks to months. LED therapy can be provided in an office or home setting.LED therapy utilizes a device (e.g., Anodyne Therapy System, Pain-X-2000, BioScan, Light Force Therapy) that delivers light to targeted tissue. This is done through multiple superluminous infrared diodes located on a flexible pad that is in contact with the skin. LED therapy may also be referred to as monochromatic infrared energy (MIRE™), infrared energy therapy, infrared light therapy or infrared heating pad system.
Light emitting diode therapy for the treatment of conditions / diseases, including but not limited to diabetic peripheral neuropathy, lymphedema, non-healing wounds, tendonitis, capsulitis, and pain is considered investigational.
See also: Laser Therapy for Onychomycosis and Active Acne
Any specific products referenced in this policy are just examples and are intended for illustrative purposes only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available. These examples are contained in the parenthetical e.g. statement.
We develop Medical Policies to provide guidance to Members and Providers. This Medical Policy relates only to the services or supplies described in it. The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy. For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed. If there is a conflict between the Medical Policy and a health plan, the express terms of the health plan will govern.
Scientific evidence in peer review literature is lacking regarding the use, safety, and effectiveness on health outcomes.
Ammar, T. (2012) Monochromatic infrared photo energy in diabetic peripheral neuropathy. International Scholarly Research Network Rehabilitation. Volume 2012, Article ID 484307. (Level 2 evidence)
Center for Medicare & Medicaid Services. CMS.gov. (2007, January) National Coverage Determination (NCD): for Infrared Therapy Devices (270.6). Retrieved October 2, 2017 from https://www.cms.gov.
de Andrade, A., Bossini, P., and Parizotto, N. (2016, November) Use of low level laser therapy to control neuropathic pain: a systematic review. Journal of Photochemistry & Photobiology, 164, 36-42. Abstract retrieved October 2, 2017 from PubMed database.
Hsieh, R., Lo, M., Lee, W., & Liao, W. (2012). Therapeutic effects of short-term monochromatic infrared energy therapy on patients with knee osteoarthritis: a double-blind, randomized, placebo-controlled study. Journal of Orthopaedic & Sports Physical Therapy, 42 (11), 947-956. (Level 1 evidence)
Robinson, C., Klahr, P., Stein, C., Sbruzzi, G., & Plentz, R. (2015). Effects of monochromatic infrared energy in patients with diabetic peripheral neuropathy: a meta-analysis of randomized clinical trials. Eiabetology & Metabolic Syndrome, 2015, 7 (Suppl 1), A16. (Level 1 evidence)
U. S. Food and Drug Administration. (2006, December). Center for Devices and Radiological Health. 510(k) Premarket notification database K062635. Retrieved December 22, 2015 from: http://www.accessdata.fda.gov.
U. S. Food and Drug Administration. (2011, January). Center for Devices and Radiological Health. 510(k) Premarket notification database K101894. Retrieved December 22, 2015 from: http://www.accessdata.fda.gov.
ORIGINAL EFFECTIVE DATE: 12/1/2003
MOST RECENT REVIEW DATE: 11/9/2017
Policies included in the Medical Policy Manual are not intended to certify coverage availability. They are medical determinations about a particular technology, service, drug, etc. While a policy or technology may be medically necessary, it could be excluded in a member's benefit plan. Please check with the appropriate claims department to determine if the service in question is a covered service under a particular benefit plan. Use of the Medical Policy Manual is not intended to replace independent medical judgment for treatment of individuals. The content on this Web site is not intended to be a substitute for professional medical advice in any way. Always seek the advice of your physician or other qualified health care provider if you have questions regarding a medical condition or treatment.
This document has been classified as public information.